- Conditions
- Bacterial Disease Carrier, Cystic Fibrosis
- Interventions
- Placebo, WRAIR-PAM-CF1
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 462
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder, ADHD
- Interventions
- ABT-894, atomoxetine, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 22
- States / cities
- San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
- Conditions
- Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
- Interventions
- Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
- Drug · Behavioral
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 6 Years to 14 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Stony Brook, New York
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Cannabigerol, Placebo
- Drug · Other
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- IR Viloxazine, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
- Conditions
- Neoplasm of Pancreas, IPMN, Pancreatic
- Interventions
- Vitamin E Delta Tocotrienol, Placebo
- Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Omaha, Nebraska
- Conditions
- Acute Lung Injury
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Loma Linda, California • Sacramento, California + 16 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 45
- States / cities
- Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
- Conditions
- Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
- Interventions
- IV lidocaine, Placebos
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- ADHD
- Interventions
- SPD503-AM, SPD503-PM, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Interventions
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
- Interventions
- Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
- Device · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years to 215 Months
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Naltrexone, Methylphenidate Abuse
- Interventions
- Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
- Drug
- Lead sponsor
- Avekshan LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation, Revascularization
- Interventions
- Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control, Placebo Beetroot Juice Without Nitrate
- Behavioral · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Downey, California • Atlanta, Georgia + 3 more
- Conditions
- Pregnancy Related, Gestational Weight Gain, Postpartum Weight Retention, Overweight and Obesity
- Interventions
- GROWell (Interactive Obesity Treatment Approach), Attention Support Control
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- ADHD, Substance Abuse
- Interventions
- Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more
- Conditions
- Axial Spondyloarthrithis, Ankylosing Spondylitis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
- Conditions
- Parkinson's Disease
- Interventions
- Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
- Conditions
- Insomnia, Depression
- Interventions
- CBT for Insomnia (CBT-I), Sleep Hygiene (SH)
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Aptensio XR, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Durham, North Carolina
- Conditions
- Influenza
- Interventions
- Oseltamivir, Placebo
- Drug
- Lead sponsor
- Marshfield Clinic Research Foundation
- Other
- Eligibility
- 1 Year to 79 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Marshfield, Wisconsin